Zydus Wellness Limited (ZYDUSWELL.NS)
- Previous Close
1,691.50 - Open
1,693.90 - Bid --
- Ask --
- Day's Range
1,684.30 - 1,722.60 - 52 Week Range
1,493.20 - 2,484.00 - Volume
15,507 - Avg. Volume
34,205 - Market Cap (intraday)
109.349B - Beta (5Y Monthly) -0.10
- PE Ratio (TTM)
33.11 - EPS (TTM)
51.78 - Earnings Date May 9, 2025 - May 10, 2025
- Forward Dividend & Yield 5.00 (0.30%)
- Ex-Dividend Date Jul 19, 2024
- 1y Target Est
2,214.67
Zydus Wellness Limited engages in the development, production, marketing, and distribution of health and wellness products in India. It provides sugar substitute products under the Sugar Free Gold, Sugar Free Natura, and Sugar Free Green brands; milk-based health food drink under the Complan brand; glucose-based beverage under the Glucon-D brand; and I'm lite a blended sugar coated with stevia. The company offers a range of skincare products, such as soap-free face washes, face masks, scrubs, and leave-on-products under the Everyuth brand; prickly heat and cooling powder, and hand sanitizer under the Nycil brand; and probiotic butter spread, table spread, ghee, butter, cholesterol fat-free spread, mayonnaise, and chocolate spread under the Nutralite brand. It exports its products. The company was formerly known as Carnation Nutra Analogue Foods Limited and changed its name to Zydus Wellness Limited in January 2009. The company was founded in 1988 and is based in Ahmedabad, India. Zydus Wellness Limited is a subsidiary of Zydus Lifesciences Limited.
www.zyduswellness.com1,008
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: ZYDUSWELL.NS
View MorePerformance Overview: ZYDUSWELL.NS
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZYDUSWELL.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZYDUSWELL.NS
View MoreValuation Measures
Market Cap
107.88B
Enterprise Value
105.29B
Trailing P/E
33.09
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.21
Price/Book (mrq)
1.96
Enterprise Value/Revenue
4.12
Enterprise Value/EBITDA
28.13
Financial Highlights
Profitability and Income Statement
Profit Margin
12.62%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
25.78B
Net Income Avi to Common (ttm)
3.25B
Diluted EPS (ttm)
51.78
Balance Sheet and Cash Flow
Total Cash (mrq)
3.88B
Total Debt/Equity (mrq)
2.80%
Levered Free Cash Flow (ttm)
--